<DOC>
	<DOCNO>NCT01715636</DOCNO>
	<brief_summary>This study aim describe safety , tolerability adherence coformulated anti-HIV drug tenofovir-emtricitabine-rilpivirine ( eviplera ) give men sex men ( MSM ) follow actual potential sexual exposure HIV . This biomedical intervention know nonoccupational post-exposure prophylaxis ( NPEP ) . Patients receive NPEP meet criterion outline 2007 National Australian NPEP Guidelines . Three two anti-HIV drug administer 28-days depend severity assess HIV acquisition risk . In study eviplera would constitute 3-drug NPEP . Tenofovir-emtricitabine ( truvada ) component eviplera use NPEP SVH since 2006 . This multi site , prospective , open-label , non-randomised trial . Participants MSM present various recruitment site request NPEP . Initially , 50 eligible participant assign receive eviplera 25mg daily take food 28-days accord establish Australian guideline use 3-drug NPEP . There 7 visit 12-week period . Follow-up post NPEP 8 week . If interim analysis demonstrate acceptable safety , propose seek ethic approval increase sample size 100 patient gain accurate information regimen completion rate on-drug adherence . The primary study objective : 1 . To describe safety 28 day NPEP use co-formulated FTC-RPV-TDF 2 . To describe tolerability 28 day NPEP use FTC-RPV-TDF 3 . To describe on-drug adherence regimen completion rate 28 day NPEP use FTC-RPV-TDF</brief_summary>
	<brief_title>Safety , Tolerability , Adherence Co-formulated Tenofovir-emtricitabine-rilpivirine Used HIV Nonoccupational Post-exposure Prophylaxis Men Who Have Sex With Men .</brief_title>
	<detailed_description />
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Man sex men 2 . Age least 18 year 3 . Eligible 3drug NPEP accord Australian guideline use 3drug NPEP follow actual potential sexual exposure HIV receptive anal intercourse unknown source 4 . Able provide write , inform consent 5 . Able commit study visit 6 . Nonsexual exposure 7 . Exposure occur sex man woman 8 . HIV infection diagnose day 1 serological test include indeterminate serology consistent possible primary HIV infection 9 . Use medication contraindicate FTCRPVTDF 10 . Serum hepatic transaminase ( alanine aminotransferase [ ALT ] great 5 time upper limit normal range 11 . Serum estimate Glomerular Filtration Rate ( eGFR ) &lt; 60mL/min/ BSAc 12 . Current therapy hepatitis B 13 . Day 1 serological evidence chronic/active hepatitis B 14 . Previous NPEP contain FTCRPVTDF 15 . A patient history current evidence condition , therapy , laboratory abnormality , circumstance might confound result study , interfere patient 's participation full duration study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>